Global Genome Editing Market, By Technique (CRISPR, TALENs, Zinc Finger Nucleases, Others), By Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others), By Delivery Method (Ex-vivo, In-vivo), By End User (Pharmaceutical & Biotechnology Companies, Clinical Research Organization, Research Institutes), By Region, Competition Forecast & Opportunities, 2026
Global Nanopore Sequencing Market, By Product (Consumables v/s Instruments), By Nucleotide Sequenced (DNA v/s RNA), By Type (Direct Current Sequencing, Synthetic DNA and Horizontal Tunnelling Current Sequencing, Optical Reading Techniques Sequencing, Exonuclease Sequencing), By Type of Nanopore (Solid State, Biological, Hybrid), By Application (Human Genetics, Clinical Research, Plant Research, Microbiology, Animal Research), By End User (Biotechnology Companies, Clinical Laboratories, Academic & Research Institutes), By Region, Competition Forecast & Opportunities, 2026
Global Sleeping Aids Market: Market Segments: By Product Type (Mattresses and Pillows, Sleep Laboratory Services, Medication, Sleep Apnea Devices); By Sleep Disorder (Insomnia, Sleep Apnea, Restless Legs Syndrome, Narcolepsy, Sleep Walking); and Region Analysis of Market Size, Share & Trends for 2014 2019 and Forecasts to 2030
Clinical Trials Support Services Market Size, Share & Trends Analysis Report By Phase, By Service (IRB, Clinical Trial Site Management, Data Management, Patient Recruitment Management), By Sponsor, By Region, And Segment Forecasts, 2021 - 2028
Atypical Chemokine Receptor 3 (C-X-C Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3) - Drugs in Development, 2021
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drugs in Development, 2021
Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drugs in Development, 2021